Stockscreener 앱 받기
2.725
2.58%
0.055
전일 마감가:
$2.67
열려 있는:
$2.66
하루 거래량:
1.11M
Relative Volume:
0.52
시가총액:
$788.63M
수익:
$38.03M
순이익/손실:
$-146.40M
주가수익비율:
-6.0556
EPS:
-0.45
순현금흐름:
$-121.38M
1주 성능:
-0.76%
1개월 성능:
-1.12%
6개월 성능:
-28.86%
1년 성능:
-36.89%
1일 변동 폭
$2.61
$2.77
1주일 범위
$2.57
$2.77
52주 변동 폭
$2.335
$6.055
앱셀레라바이오로직스 Stock (ABCL) Company Profile
명칭
Abcellera Biologics Inc
전화
(604) 559-9005
주소
2215 YUKON STREET, VANCOUVER
ABCL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| ABCL | 2.725 | 788.63M | 38.03M | -146.40M | -121.38M | -0.45 |
| VRTX | 449.81 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.30 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 595.77 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.16 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.17 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
앱셀레라바이오로직스 Stock (ABCL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-20 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2024-02-22 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-12-05 | 개시 | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-10-13 | 재개 | Piper Sandler | Overweight |
| 2023-02-28 | 개시 | Cowen | Outperform |
| 2022-12-15 | 개시 | Goldman | Buy |
| 2022-11-16 | 개시 | Truist | Buy |
| 2021-12-21 | 개시 | The Benchmark Company | Buy |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2021-01-05 | 개시 | Berenberg | Buy |
| 2021-01-05 | 개시 | Credit Suisse | Outperform |
| 2021-01-05 | 개시 | SVB Leerink | Outperform |
| 2021-01-05 | 개시 | Stifel | Buy |
모두보기
앱셀레라바이오로직스 주식(ABCL)의 최신 뉴스
ABCL (AbCellera Biologics) Goodwill-to-Asset : 0.03 (As of Sep. 2024) - GuruFocus.com
ABCL (AbCellera Biologics) EBIT per Share : $-1.00 (TTM As of Sep. 2024) - GuruFocus.com
GSA Capital Partners LLP Boosts Stock Position in AbCellera Biologics Inc. (NASDAQ:ABCL) - MarketBeat
AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Sold by Baillie Gifford & Co. - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Bloom Burton Cuts Earnings Estimates for AbCellera Biologics - MarketBeat
Adv Micro Devices (AMD-Q) QuotePress Release - The Globe and Mail
Abcellera Biologics Inc (ABCL-Q) QuotePress Release - The Globe and Mail
Palantir Technologies Inc Cl A (PLTR-N) QuotePress Release - The Globe and Mail
AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024 - Business Wire
AbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Have Been Cutting Their Estimates - Simply Wall St
Leerink Partnrs Has Pessimistic View of ABCL FY2024 Earnings - MarketBeat
AbCellera Unveils Breakthrough T-Cell Platform Data, Shows Promise in Cancer Treatment | ABCL Stock News - StockTitan
AbCellera Biologics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
AbCellera Biologics (NASDAQ:ABCL) Given "Hold" Rating at Benchmark - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Given "Buy" Rating at Stifel Nicolaus - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Shares Gap Down After Earnings Miss - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
AbCellera stock price target cut, keeps Outperform on strategic pivot By Investing.com - Investing.com UK
AbCellera Biologics Inc. (NASDAQ:ABCL) Q3 2024 Earnings Call Transcript - Insider Monkey
AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Misses Revenue Estimates - MSN
AbCellera Biologics Inc (ABCL) Q3 2024 Earnings Call Highlights: Navigating Challenges with ... By GuruFocus - Investing.com Canada
Earnings call: AbCellera reports steady Q3 2024 revenue amidst R&D growth - Investing.com
AbCellera Biologics Inc (ABCL) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic Developments - GuruFocus.com
AbCellera Biologics Inc (ABCL) Q3 2024 Earnings Call Highlights: Navigating Challenges with ... - Yahoo Finance
AbCellera Reports Q3 2024 Business Results - The Globe and Mail
AbCellera Biologics Reports Q3 2024 Financial Results - TipRanks
AbCellera Biologics (ABCL) Q3 2024 Earnings Call Transcript - Nasdaq
Nasdaq Insurance Index (INSR) QuotePress Release - The Globe and Mail
TSX Industrials Capped Index (TTIN) QuotePress Release - The Globe and Mail
Abcellera Biologics earnings beat, revenue fell short of estimates By Investing.com - Investing.com UK
AbCellera Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
McDonald's Corp (MCD-N) QuotePress Release - The Globe and Mail
Laureate Education Inc (LAUR-Q) QuotePress Release - The Globe and Mail
AbCellera Biologics Inc (ABCL) Q3 2024: Everything You Need To K - GuruFocus.com
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
TSX Communication Services Capped Index (TTTS) QuotePress Release - The Globe and Mail
AbCellera Biologics (ABCL) Set to Announce Quarterly Earnings on Monday - MarketBeat
TSX Renewable and Clean Tech Index (TXCT) QuotePress Release - The Globe and Mail
AbCellera to Present at Upcoming Investor Conferences in November 2024 - Business Wire
3 Promising Penny Stocks On US Exchanges With Over $600M Market Cap - Yahoo Finance
Is AbCellera Biologics Inc. (ABCL) the Penny Stock with the Biggest Upside Potential According to Analysts? - Insider Monkey
AbCellera Biologics (NASDAQ:ABCL) Shares Down 5%Here's What Happened - MarketBeat
AbCellera: A Platform To Pipeline Transition - Seeking Alpha
AbCellera Biologics (NASDAQ:ABCL) Trading Up 5.2%Here's What Happened - MarketBeat
AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024 - Lucknow Sentinel
Dark Forest Capital Management LP Buys 45,721 Shares of AbCellera Biologics Inc. (NASDAQ:ABCL) - Defense World
AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Acquired by Renaissance Technologies LLC - MarketBeat
AbCellera Biologics Inc. (NASDAQ:ABCL) Receives $14.20 Average Price Target from Analysts - MarketBeat
Wall Street SWOT: AbCellera stockBiotech firm's platform shows promise amid challenges - Investing.com
AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024 - BioSpace
앱셀레라바이오로직스 (ABCL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):